Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies
AUTOR(ES)
Ré, Viviana, Gallego, Sandra, Treviño, Elena, Barbás, Gabriela, Domínguez, Claudia, Elbarcha, Osvaldo, Bepre, Héctor, Contigiani, Marta
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2005-05
RESUMO
This study was conducted to compare among the most recent generation of five screening tests licensed in Argentina, in order to evaluate which of the tests has the best sensitivity for detection of antibodies against hepatitis C virus (HCV). The tests analyzed were: Detect-HCV™ (3.0) Biochem ImmunoSystems, Canada; Hepatitis C EIA Wiener Lab., Argentina; Equipar HCV Ab, Italy; Murex HCV 4.0, UK and Serodia-HCV particles agglutination test, Japan. The results obtained showed high discrepancy between the different kits used and show that some of the tests assessed have a low sensitivity for anti-HCV detection in both chronic infections and early seroconversion, and indicate that among the commercially available kits in Argentina, Murex HCV 4.0 (UK) and Serodia-HCV particles agglutination test (Japan) have the best sensitivity for HCV screening. Although the sensitivity of the assays is the first parameter to be considered for blood screening, more studies should be carried out to assess the specificity of such assays.
Documentos Relacionados
- Screening tests for antibodies to cytomegalovirus: an evaluation of five commercial products.
- Evaluation of screening tests for the detection of antistreptolysin O antibodies.
- Definition of False-Positive Reactions in Screening for Hepatitis C Virus Antibodies
- Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.
- Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA.